迪卡斯 DCTH 深 沪
已收盘 12-19 16:00:00 美东时间
10.06
+0.130
+1.31%
华盛通- 最 高10.65
- 今 开9.93
- 成交量 31.97万股
- 最 低 9.03
- 昨 收 9.93
- 总市值 7954.14万
- 52周最高 18.23
- 市盈率 静 --
- 换手率 4.04%
- 52周最低 8.12
- 委 比 37.13%
- 总股本 790.67万
- 历史最高 149900800000.00
- 量 比 0.61
- 振 幅 16.31%
- 历史最低 1.10
- 每 手 1
- 风险率 2.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Delcath Systems Announces $25M Buyback Plan
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath") an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a
11-21 05:02
Delcath三季度营收低于预期，并下调全年指引
美股周一早盘，肿瘤药物开发企业Delcath Systems（DCTH）股价下跌10%，此前该公司报告第三季度营收2050万美元，略低于预期，并下调了全年指引。尽管如此，凭借其无负债状况和强劲现金储备，公司仍对2024年治疗量实现150%的增长持乐观态度。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
10-20 21:50
HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $24
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $22 to $24.
03-07 20:07
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
On CNBC's “Mad Money Lightning Round,” Jim Cramer said, “This is a very speculative situation,” when asked about ADMA Biologics, Inc. (NASDAQ:ADMA). “Any time there's immunity-compromised patients, there's some big money down the road,” he added. On Aug. 8, ADMA Biologics reported better-than-expect...
2024-08-30 21:09
Delcath Systems Shares Rise After Positive Hepatic Perfusion Study Results
01:03 PM EDT, 08/27/2024 (MT Newswires) -- Delcath Systems' (DCTH) shares jumped 10% in recent Tuesday trading after the company reported "positive outcomes" from an independent study on hepatic perfusion for patients with uveal melanoma. A retrospective 30-patient study found the company's Hepzato ...
2024-08-28 01:03
Delcath Systems Publishes Retrospective Study By Independent Investigators In The Annals Of Surgical Oncology. The Study, Titled "Hepatic And Overall Progression-free Survival After Percutaneous Hepatic Perfusion (PHP) As First-line Or Second-line Therapy For Metastatic Uveal Melanoma,"
Key Findings from the Study: Overall Survival (OS): The study reported median OS of 22.4 months for patients treated with HEPZATO KIT as a first-line therapy (N=17) and 18.4 months as a second-line therapy (N=6). Hepatic Progression-Free Survival (hPFS): Patients receiving HEPZATO KIT as first-line ...
2024-08-27 20:34
Delcath Systems Announces Publication Of An Independent Study Conducted By Investigators At The University Hospital Of Leipzig, Germany, Titled "Hepatic Chemosaturation With Melphalan In Patients With Primary Or Secondary Liver Tumors With Or Without Extrahepatic Tumor Manifestation,"
Delcath Systems, Inc. (NASDAQ:DCTH) ("Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study conducted by investigators at the University Hospital of Leipzig, Germany, in the...
2024-08-27 04:05
